Cost-Effectiveness of Sorafenib for Metastatic Renal Cell Carcinoma: A Systematic Review
International Pharmacy Acta,
Vol. 2 No. 1 (2019),
16 December 2019
,
Page 2e10:1-6
https://doi.org/10.22037/ipa.v2i1.24856
Abstract
- Introduction: Sorafenib is a multi-kinase inhibitor and decreases tumor cell proliferation. This study aimed to systematically review the existing evidence related to its cost-effectiveness.
- Methods and Results: EMBASE, MEDLINE, PUBMED, Google Scholar, and the Scopus database were searched and articles were selected on the basis of their correlation with the economic evaluations of Sorafenib. The quality of the selected studies was assessed using the Quality of Health Economic Studies instrument. This review revealed costs per quality-adjusted life years in the range of US $89,160 to $118,825, depending on whether the setting was first-line or second-line and which comparator is utilized. The results indicated that Sorafenib had not been considered as an appropriate treatment option for patients with metastasis Renal Cell Carcinoma (mRCC). Sorafenib was dominated (i.e. higher cost and lower efficacy) in comparison with Sunitinib in all cases. However, Sorafenib would be more cost-effective in comparison with bevacizumab plus interferon alfa in the treatment of mRCC.
- Conclusion: Sorafenib was more effective with higher cost than Best Supportive Care but Sorafenib was not cost-effective in view of current willingness to pay threshold.
- renal cell carcinoma
- pharmacoeconomic evaluation
- Sorafenib
- cost-effectiveness
- systematic review
How to Cite
References
Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality. Eur Urol [Internet]. 2015 Mar;67(3):519–30. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0302283814010100
Petrou P, Talias MA. Cost–effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus. Expert Rev Pharmacoecon Outcomes Res [Internet]. 2014 Feb 7;14(1):131–8. Available from: http://doi.wiley.com/10.1111/j.1464-410X.2010.09957.x
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374–403.
Cancer Stat Facts: Kidney and Renal Pelvis Cancer [Internet]. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html
Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol [Internet]. 2001 Nov;166(5):1611–23. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534705656406
Norum J, Nieder C, Kondo M. Sunitinib, Sorafenib, Temsirolimus or Bevacizumab in Thetreatment of Metastatic Renal Cell Carcinoma: A Review of Health Economic Evaluations. J Chemother. 2010 Apr;22(2):75–82.
Calvo Aller E, Maroto P, Kreif N, González Larriba JL, López-Brea M, Castellano D, et al. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Vol. 13, Clinical and Translational Oncology. 2011. p. 869–77.
Purmonen TT. Cost–effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):383–93.
Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 2008 May;34(3):193–205.
Chen S, Peng Z, Wei M, Liu W, Dai Z, Wang H, et al. Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis. BMC Cancer. 2018 Dec;18(1):392.
Hoyle M, Green C, Thompson-Coon J, Liu Z, Welch K, Moxham T, et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Vol. 13, Value Health. 2010. p. 55–60.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med [Internet]. 2007 Jan 11;356(2):125–34. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa060655
Casciano R, Chulikavit M, Di Lorenzo G, Liu Z, Baladi J-F, Wang X, et al. Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib. Value Heal. 2011 Sep;14(6):846–51.
Casciano R, Chulikavit M, Di Lorenzo G, Liu Z, Baladi J-F, Wang X, et al. Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib. Value Heal [Internet]. 2011 Sep;14(6):846–51. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1098301511014835
Benedict Á, Figlin RA, Sandström P, Harmenberg U, Ullén A, Charbonneau C, et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int [Internet]. 2011 Feb 7;14(1):665–72. Available from: http://www.tandfonline.com/doi/full/10.1586/14737167.2014.873703
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. J Clin Oncol [Internet]. 2009 Jul 10;27(20):3312–8. Available from: http://ascopubs.org/doi/10.1200/JCO.2008.19.5511
Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol [Internet]. 2009 Mar 10;27(8):1280–9. Available from: http://ascopubs.org/doi/10.1200/JCO.2008.19.3342
- Abstract Viewed: 187 times
- PDF Downloaded: 151 times